EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review

Francesco Amati iD, Anna Stainer iD, Veronica Polelli, Marco Mantero, Andrea Gramegna iD, Francesco Blasi iD, Stefano Aliberti

International Journal of Molecular Sciences · 25.04.2023 · 24 (9) · 7849

DOI: 10.3390/ijms24097849 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 25.04.2023. Verfasst von Francesco Amati und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide. These drugs have been shown to reduce the rate of decline in forced vital capacity and the risk of acute exacerbation among patients with idiopathic pulmonary fibrosis. Recent data suggest that different interstitial lung diseases with a progressive pulmonary fibrosis phenotype can share similar pathogenetic and biological pathways and could be amenable to antifibrotic therapies. Indeed, historical management strategies in interstitial lung disease have failed to identify potential treatments once progression has occurred despite available drugs. In this systematic review, we summarized data on the efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis as well as ongoing and upcoming clinical trials. We identify two well-designed trials regarding nintedanib demonstrating the efficacy of this drug in slowing disease progression in patients with interstitial lung diseases other than idiopathic pulmonary fibrosis. On the other hand, results on the use of pirfenidone in interstitial lung diseases other than idiopathic pulmonary fibrosis should be interpreted with more caution on the basis of trial limitations. Several randomized control trials are underway to improve the quality of evidence in the interstitial lung disease field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisLung Diseases, InterstitialHumansIndolesPyridonesTreatment Outcome

Stichwörter der Autor:innen

efficacyforced vital capacityinterstitial lung diseasesnintedanibpirfenidone

Substanzen

nintedanibpirfenidoneIndolesPyridones

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy.
  • Respiratory Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.
  • Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
  • Department of Pathophysiology and Transplantation, Università degli Studi di Milano, 20122 Milan, Italy.

ORCID-Profile: Francesco Amati, Anna Stainer, Andrea Gramegna, Francesco Blasi

Zitieren

APA

Amati, F., Stainer, A., Polelli, V., Mantero, M., Gramegna, A., Blasi, F., & Aliberti, S. (2023). Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review. International Journal of Molecular Sciences, 24(9), 7849. https://doi.org/10.3390/ijms24097849

Vancouver

Amati F, Stainer A, Polelli V, Mantero M, Gramegna A, Blasi F, et al. Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review. International Journal of Molecular Sciences. 2023;24(9):7849. doi:10.3390/ijms24097849

BibTeX
@article{Amati2023,
  author = {Amati, Francesco and Stainer, Anna and Polelli, Veronica and Mantero, Marco and Gramegna, Andrea and Blasi, Francesco and Aliberti, Stefano},
  title = {Efficacy of Pirfenidone and Nintedanib in Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis: A Systematic Review},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {9},
  pages = {7849},
  doi = {10.3390/ijms24097849}
}
Kostenlos starten →